All In Biotech

Drug Trial Radar · NCT00575588

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.

Last checked: Nov 20, 2026Latest source record: Mar 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 891 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

891

Actual

Start

Dec 2007

Primary completion

Aug 2009

Study completion Aug 2010

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.

Conditions

  • Type 2 Diabetes

Interventions

  • MetforminDrug

    open-label metformin

  • SulphonylureaDrug

    Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)

  • SaxagliptinDrug

    Saxagliptin 5 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin A1c (HbA1c) Change From Baseline to Week 52Time frame: Baseline to 52 Weeks

Locations

94 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Hanko, Finland

  • Research Site

    Helsinki, Finland

  • Research Site

    Kuopio, Finland

  • Research Site

    Kuusankoski, Finland

  • Research Site

    Mikkeli, Finland

  • Research Site

    Oulu, Finland

  • Research Site

    Tampere, Finland

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Dortmund, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Mainz, Germany

  • Research Site

    Mannheim, Germany

  • Research Site

    Mülheim, Germany

  • Research Site

    Pirna, Germany

  • Research Site

    Ratzeburg, Germany

  • Research Site

    Reinfeld, Germany

  • Research Site

    Rhaunen, Germany

  • Research Site

    Schmiedeberg, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Wahlstedt, Germany

  • Research Site

    Weinheim, Germany

  • Research Site

    Balatonfüred, Hungary

  • Research Site

    Békéscsaba, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Gyula, Hungary

  • Research Site

    Kalocsa, Hungary

  • Research Site

    Kaposvár, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Mosonmagyaróvár, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Székesfehérvár, Hungary

  • Research Site

    Bangalore, Karnataka, India

  • Research Site

    Indore, Madhya Pradesh, India

  • Research Site

    Mumbai, Mashatra, India

  • Research Site

    Jaipur, Rajasthan, India

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.